GGrantIndex
← Leaderboards

Victoria L. Seewaldt

Duke University

$17,302,500
Attributed
$26,652,958
Total exposure
19
Grants
16
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.6M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$40,118,834 · 24

By mechanism

R01$18,222,689 · 8
U54$9,845,160 · 5
P20$6,140,057 · 6
U01$3,967,166 · 1
T32$1,588,579 · 1
P30$334,183 · 1

Top collaborators

Most similar at Duke University

Same institution · by research overlap

Others in their field

Top investigators on “Woman

Research focus

WomanAfrican AmericanMalignant Breast NeoplasmMalignant NeoplasmsMammary GlandGrantCohortFundingProgramsHigh RiskResearch PersonnelHigh Risk WomanTriple-Negative Invasive Breast CarcinomaCommunitiesCellsLinkMolecularCancer InitiationUniversitiesCity Of Hope Comprehensive Cancer CenterBaseBreastResourcesTraining

Grant awards (109)

1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$1,380,454
U54 · FY2025 · CA · contact PI
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$1,356,807
U54 · FY2025 · CA
Administrative Core$409,026
U54 · FY2025 · CA · contact PI
Cancer Metabolism Training Program$275,859
T32 · FY2025 · CA
Pilot Project 1$116,864
U54 · FY2025 · CA · contact PI
Population Facing Research$114,153
P30 · FY2025 · CA · contact PI
Core 4: Shared Resource - Capacity Development$73,040
U54 · FY2025 · CA · contact PI
1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$1,311,431
U54 · FY2024 · CA · contact PI
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$1,290,685
U54 · FY2024 · CA
Administrative Core$249,799
U54 · FY2024 · CA · contact PI
Cancer Metabolism Training Program$248,089
T32 · FY2024 · CA
Core 4: Shared Resource - Capacity Development$208,165
U54 · FY2024 · CA · contact PI
Population Facing Research$120,419
P30 · FY2024 · CA · contact PI
Pilot Project 1$111,020
U54 · FY2024 · CA · contact PI
1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$1,380,454
U54 · FY2023 · CA · contact PI
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$1,358,485
U54 · FY2023 · CA
Translational Research Center in Lung Cancer Disparities (TRACER)$1,021,757
P20 · FY2023 · CA
Administrative Core$262,946
U54 · FY2023 · CA · contact PI
Core 4: Shared Resource - Capacity Development$219,120
U54 · FY2023 · CA · contact PI
TRACER Developmental Research Program$145,691
P20 · FY2023 · CA · contact PI
Pilot Project 1$116,864
U54 · FY2023 · CA · contact PI
Population Facing Research$99,611
P30 · FY2023 · CA · contact PI
Translational Research Center in Lung Cancer Disparities (TRACER)$1,035,561
P20 · FY2022 · CA
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$324,404
P20 · FY2022 · CA
Cancer Metabolism Training Program$219,265
T32 · FY2022 · CA
1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$211,607
P20 · FY2022 · CA · contact PI
Admin-Core$178,131
P20 · FY2022 · CA · contact PI
TRACER Developmental Research Program$154,217
P20 · FY2022 · CA · contact PI
Translational Research Center in Lung Cancer Disparities (TRACER)$1,183,609
P20 · FY2021 · CA
Epigenetic damage in women living in LA food-desert zip codes$700,381
R01 · FY2021 · CA · contact PI
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$272,883
P20 · FY2021 · CA
1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$241,905
P20 · FY2021 · CA · contact PI
Cancer Metabolism Training Program$238,561
T32 · FY2021 · CA
TRACER Developmental Research Program$172,296
P20 · FY2021 · CA · contact PI
Admin-Core$34,054
P20 · FY2021 · CA · contact PI
Epigenetic damage in women living in LA food-desert zip codes$900,360
R01 · FY2020 · CA · contact PI
Combined breast MRI/biomarker strategies to identify aggressive biology$649,862
U01 · FY2020 · CA · contact PI
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$305,324
P20 · FY2020 · CA
1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$241,905
P20 · FY2020 · CA · contact PI
Cancer Metabolism Training Program$189,558
T32 · FY2020 · CA
Admin-Core$34,054
P20 · FY2020 · CA · contact PI
Epigenetic damage in women living in LA food-desert zip codes$679,592
R01 · FY2019 · CA · contact PI
Combined breast MRI/biomarker strategies to identify aggressive biology$656,559
U01 · FY2019 · CA · contact PI
Tension-Stat3-miR-mediated metastasis$530,570
R01 · FY2019 · CA
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$306,700
P20 · FY2019 · CA
1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership$241,905
P20 · FY2019 · CA · contact PI
Cancer Metabolism Training Program$215,803
T32 · FY2019 · CA
Combined breast MRI/biomarker strategies to identify aggressive biology$178,623
U01 · FY2019 · CA · contact PI
Admin-Core$34,054
P20 · FY2019 · CA · contact PI
Epigenetic damage in women living in LA food-desert zip codes$700,834
R01 · FY2018 · CA · contact PI
Combined breast MRI/biomarker strategies to identify aggressive biology$663,841
U01 · FY2018 · CA · contact PI
Tension-Stat3-miR-mediated metastasis$574,669
R01 · FY2018 · CA
Cancer Metabolism Training Program$201,444
T32 · FY2018 · CA
Combined breast MRI/biomarker strategies to identify aggressive biology$190,203
U01 · FY2018 · CA · contact PI
Tension-Stat3-miR-mediated metastasis$25,178
R01 · FY2018 · CA
Epigenetic damage in women living in LA food-desert zip codes$719,296
R01 · FY2017 · CA · contact PI
Combined breast MRI/biomarker strategies to identify aggressive biology$695,009
U01 · FY2017 · CA · contact PI
Tension-Stat3-miR-mediated metastasis$576,372
R01 · FY2017 · CA
Diversity Supplement to Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology$190,203
U01 · FY2017 · CA · contact PI
Tension-Stat3-miR-mediated metastasis$580,933
R01 · FY2016 · CA
Targeted Chemoprevention of Breast Cancer: From the Bench to Clinical Testing$335,466
R01 · FY2016 · CA · contact PI
Combined breast MRI/biomarker strategies to identify aggressive biology$698,567
U01 · FY2015 · CA · contact PI
Mechanisms of breast cancer associated with obesity$602,173
R01 · FY2015 · CA
Tension-Stat3-miR-mediated metastasis$595,412
R01 · FY2015 · CA
Targeted Chemoprevention of Breast Cancer: From the Bench to Clinical Testing$192,596
R01 · FY2015 · CA · contact PI
KCNK9 Imprinting in Breast Cancer Progression and Metastasis$179,984
R01 · FY2015 · CA · contact PI
Targeted Chemoprevention of Breast Cancer: From the Bench to Clinical Testing$154,523
R01 · FY2015 · CA · contact PI
KCNK9 Imprinting in Breast Cancer Progression and Metastasis$145,791
R01 · FY2015 · CA · contact PI
Targeted Chemoprevention of Br Ca: From Bench to Clinical Testing Minority Suppl$103,153
R01 · FY2015 · CA · contact PI
Mechanisms of breast cancer associated with obesity$87,433
R01 · FY2015 · CA
Combined breast MRI/biomarker strategies to identify aggressive biology$44,299
U01 · FY2015 · CA · contact PI
Gordon Research Conference in Mammary Gland Biology 2015$15,000
R13 · FY2015 · CA · contact PI
Mechanisms of breast cancer associated with obesity$588,295
R01 · FY2014 · CA
KCNK9 Imprinting in Breast Cancer Progression and Metastasis$316,002
R01 · FY2014 · CA · contact PI
Targeted Chemoprevention of Breast Cancer: From the Bench to Clinical Testing$312,910
R01 · FY2014 · CA · contact PI
Mechanisms of breast cancer associated with obesity$86,424
R01 · FY2014 · CA
2014, 2015 and 2016 Mammary Gland Biology Gordon Research Conference & Gordon Res$6,000
R13 · FY2014 · ES · contact PI
Mechanisms of breast cancer associated with obesity$574,175
R01 · FY2013 · CA
KCNK9 Imprinting in Breast Cancer Progression and Metastasis$306,229
R01 · FY2013 · CA · contact PI
Targeted Chemoprevention of Breast Cancer: From the Bench to Clinical Testing$303,232
R01 · FY2013 · CA · contact PI
KCNK9 Imprinting in Breast Cancer Progression and Metastasis$40,719
R01 · FY2013 · CA · contact PI
Mechanisms of breast cancer associated with obesity$644,288
R01 · FY2012 · CA
Targeted Chemoprevention of Breast Cancer: From the Bench to Clinical Testing$336,837
R01 · FY2012 · CA · contact PI
KCNK9 Imprinting in Breast Cancer Progression and Metastasis$325,775
R01 · FY2012 · CA · contact PI
KCNK9 Imprinting in Breast Cancer Progression and Metastasis$86,921
R01 · FY2012 · CA · contact PI
KCNK9 Imprinting in Breast Cancer Progression and Metastasis$325,775
R01 · FY2011 · CA · contact PI
KCNK9 Imprinting in Breast Cancer Progression and Metastasis$43,062
R01 · FY2011 · CA · contact PI
Molecular markers of breast cancer risk and prevention$261,331
R01 · FY2010 · CA · contact PI
ECM-Mediated Apoptosis in p53 (-) HMECs$222,477
R01 · FY2010 · CA · contact PI
Molecular markers of breast cancer risk and prevention$261,149
R01 · FY2009 · CA · contact PI
ECM-Mediated Apoptosis in p53 (-) HMECs$222,477
R01 · FY2009 · CA · contact PI
ECM-Mediated Apoptosis in p53 (-) HMECs$347,277
R01 · FY2008 · CA · contact PI
Molecular markers of breast cancer risk and prevention$261,149
R01 · FY2008 · CA · contact PI
ECM-Mediated Apoptosis in p53 (-) HMECs$81,951
R01 · FY2008 · CA · contact PI
ECM-Mediated Apoptosis in p53 (-) HMECs$347,191
R01 · FY2007 · CA · contact PI
p53 loss in HMECs: a model of breast cancer prevention$292,405
R01 · FY2007 · CA · contact PI
Molecular markers of breast cancer risk and prevention$261,149
R01 · FY2007 · CA · contact PI
ECM-Mediated Apoptosis in p53 (-) HMECs$79,998
R01 · FY2007 · CA · contact PI
Molecular markers of breast cancer risk and prevention$268,199
R01 · FY2006 · CA · contact PI
p53 loss in HMECs: a model of breast cancer prevention$267,678
R01 · FY2006 · CA · contact PI
ECM-Mediated Apoptosis in p53 (-) HMECs$217,693
R01 · FY2006 · CA · contact PI
p53 loss in HMECs: a model of breast cancer prevention$308,385
R01 · FY2005 · CA
Extracellular Matrix Mediated Apoptosis in p53 (-) HMECs$237,160
R01 · FY2005 · CA
p53 loss in HMECs: a model of breast cancer prevention$308,385
R01 · FY2004 · CA
Extracellular Matrix Mediated Apoptosis in p53 (-) HMECs$237,160
R01 · FY2004 · CA
p53 loss in HMECs: a model of breast cancer prevention$330,635
R01 · FY2003 · CA
Extracellular Matrix Mediated Apoptosis in p53 (-) HMECs$237,160
R01 · FY2003 · CA
Extracellular Matrix Mediated Apoptosis in p53 (-) HMECs$237,160
R01 · FY2002 · CA
Extracellular Matrix Mediated Apoptosis in p53 (-) HMECs$259,160
R01 · FY2001 · CA